MedPath

Telix Pharmaceuticals Doses First Patient in Phase III ProstACT GLOBAL Study of TLX591 for Prostate Cancer

• Telix Pharmaceuticals has dosed the first patient in its Phase III ProstACT GLOBAL study evaluating TLX591, a radioantibody-drug conjugate (rADC) candidate. • The ProstACT GLOBAL study aims to build upon existing data for TLX591, potentially offering benefits when combined with standard-of-care treatments like ARPI or taxanes. • TLX591 represents a potential first-in-class radioantibody-drug conjugate being evaluated in a large, mid-stage patient population for prostate cancer. • The Phase III trial will assess the efficacy and safety of TLX591 in patients with prostate cancer, with the goal of providing a new treatment option.

Telix Pharmaceuticals Limited has announced the dosing of the first patient in its Phase III ProstACT GLOBAL study, evaluating TLX591, an antibody-based prostate cancer therapy candidate. This marks a significant milestone for Telix as it advances the development of this potential first-in-class radioantibody-drug conjugate (rADC). The trial aims to assess the efficacy and safety of TLX591 in a large patient population, potentially offering a new treatment option for individuals with prostate cancer.
The ProstACT GLOBAL study is designed to build upon the existing data set for TLX591. The current TLX591 experience underlines the potential benefits of an antibody-based approach in combination with real world standards of care, including physician choice of ARPI or taxane.
Dr. Colin Hayward, Group Chief Medical Officer of Telix, stated, "Dosing a first patient in the ProstACT GLOBAL study is a significant milestone for Telix and will help build on an already extensive data set for this product candidate."
TLX591 represents a novel approach to prostate cancer treatment by combining the specificity of an antibody with the therapeutic effect of a radioisotope. This targeted delivery aims to minimize off-target effects and maximize the impact on cancer cells. The Phase III trial will further evaluate the potential of TLX591 to improve outcomes for patients with prostate cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cyclarity Therapeutics Launches First-in-Human Trial of UDP-003 for Atherosclerosis

Cyclarity Therapeutics has initiated a Phase 1 clinical trial in Australia to evaluate UDP-003, a drug targeting atherosclerosis.
The trial will assess the safety and potential efficacy of UDP-003 in removing arterial plaques by targeting oxidized cholesterol.

Ultragenyx Doses First Patient in Phase 3 Aspire Study of GTX-102 for Angelman Syndrome

Ultragenyx has initiated the Phase 3 Aspire study to evaluate GTX-102 for Angelman syndrome, a rare neurogenetic disorder.
The Aspire study will enroll 120 children aged 4-17 with Angelman syndrome, assessing cognitive and motor function improvements.

Phase 3 ProstACT GLOBAL Trial Assesses 177Lu-TLX591 in Metastatic Castration-Resistant Prostate Cancer

The ProstACT GLOBAL trial is evaluating 177Lu-TLX591 plus standard of care (SOC) versus SOC alone in metastatic castration-resistant prostate cancer (mCRPC) patients.
177Lu-TLX591 is a PSMA-targeted radionuclide therapy utilizing lutetium-177, a beta emitter, to deliver radiation directly to PSMA-positive cancer cells.

TRiCares Announces First U.S. Implantations of Topaz TTVR System in Early Feasibility Study

TRiCares has successfully implanted its Topaz transcatheter tricuspid heart valve replacement (TTVR) system in the first patients in a U.S. Early Feasibility Study.
The TRICURE EFS (NCT06506942) will evaluate the safety and performance of the Topaz TTVR system in adults with severe tricuspid regurgitation at increased operative risk.

Telix Pharmaceuticals' TLX250-CDx Phase III Trial for Kidney Cancer Imaging Doses First Patient in China

Telix Pharmaceuticals and Grand Pharmaceutical Group initiate Phase III trial (ZIRCON-CP) in China for TLX250-CDx, a PET imaging agent for clear cell renal cell carcinoma (ccRCC).
The ZIRCON-CP trial aims to demonstrate the diagnostic utility of TLX250-CDx in Chinese patients, bridging to Telix's global Phase III ZIRCON trial.

Padeliporfin VTP Shows High Complete Response Rate in UTUC Phase 3 Trial

Interim Phase 3 data shows Padeliporfin VTP achieved an 86% complete response rate in patients with low-grade upper tract urothelial cancer (UTUC).
The ENLIGHTED study evaluates Padeliporfin VTP for low-grade UTUC, offering a potential alternative to invasive surgery.

Padeliporfin VTP Shows High Complete Response Rate in Low-Grade UTUC

ImPact Biotech's Padeliporfin VTP demonstrated an 85% complete response rate in patients with low-grade upper tract urothelial cancer (UTUC).
The ENLIGHTED Phase 3 trial evaluated Padeliporfin VTP, a vascular-targeted photodynamic therapy, for treating low-grade UTUC.

Padeliporfin VTP Shows High Complete Response Rate in Low-Grade UTUC

Interim Phase 3 data shows Padeliporfin VTP achieved an 86% complete response rate in evaluable patients with low-grade upper tract urothelial cancer (UTUC).
The treatment maintains a consistent safety profile, with adverse events primarily being low-grade and resolving quickly, according to the ENLIGHTED study.

Telix Pharmaceuticals' ProstACT GLOBAL Trial Advances Theranostic Approach for Advanced Prostate Cancer

The ProstACT GLOBAL trial, sponsored by Telix Pharmaceuticals, is a Phase 3 study evaluating a novel radio antibody-drug conjugate (rADC) for advanced prostate cancer.
The rADC targets prostate-specific membrane antigen (PSMA) on cancer cells, delivering radiation therapy selectively to tumors while sparing healthy tissue.

Dimerix's First Patient Completes Phase 3 Trial and Enters DMX-200 Open Label Extension Study for Kidney Disease

Dimerix has enrolled the first patient into the Open Label Extension (OLE) study for its kidney disease drug candidate DMX-200 after completing the ACTION3 Phase 3 clinical trial.
The OLE study allows patients who have successfully completed the ACTION3 Phase 3 clinical trial to start or continue a two-year treatment of DMX-200 in an unblinded setting.

Reference News

[1]
First Patient Dosed in Phase III ProstACT GLOBAL Study of ...
telixpharma.com · Jan 10, 2024

Telix's Group Chief Medical Officer, Dr Colin Hayward, highlights the milestone of dosing the first patient in the Prost...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy